Immunocore Holdings plc 8K

Immunocore has completed target enrollment in its registrational Phase 3 TEBE‑AM trial of KIMMTRAK in previously treated advanced melanoma, with topline overall survival data anticipated by late 2026.

Immunocore Holdings plc announced that it has reached target enrollment of 540 patients in its global, randomized, registrational Phase 3 TEBE‑AM trial (NCT05549297), which is evaluating KIMMTRAK (tebentafusp) as monotherapy and in combination with pembrolizumab versus investigator’s choice in HLA-A*02:01‑positive patients with previously treated advanced melanoma whose disease has progressed after prior therapy, with overall survival as the primary endpoint and topline data expected as early as the end of 2026.

Filing Facts

CIK

1671927

Ticker

IMCR

Form

8K

Source Type

fda

Accession

0001671927-26-000026

Alert Tier

6